Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma
Authors
Keywords
Skin Rash, Vemurafenib, Eastern Cooperative Oncology Group Performance Status, Cutaneous Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma
Journal
Targeted Oncology
Volume 11, Issue 1, Pages 59-69
Publisher
Springer Nature
Online
2015-07-24
DOI
10.1007/s11523-015-0375-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: A systematic review and meta-analysis
- (2015) Omar Abdel-Rahman et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Erlotinib
- (2015) Emilie Petit-Jean et al. THERAPEUTIC DRUG MONITORING
- Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma
- (2014) B. Schilling et al. ANNALS OF ONCOLOGY
- Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients
- (2014) Vincent Launay-Vacher et al. CANCER
- Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
- (2014) Huixin Yu et al. CLINICAL PHARMACOKINETICS
- Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
- (2014) Nicolas Widmer et al. EUROPEAN JOURNAL OF CANCER
- Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients
- (2014) C. Narjoz et al. INVESTIGATIONAL NEW DRUGS
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- (2014) James Larkin et al. LANCET ONCOLOGY
- Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas
- (2013) E. Regnier-Rosencher et al. BRITISH JOURNAL OF DERMATOLOGY
- Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer
- (2013) Masahide Fukudo et al. CLINICAL PHARMACOKINETICS
- Exposure–Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma
- (2013) Masahide Fukudo et al. CLINICAL PHARMACOKINETICS
- The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
- (2013) Silvy da Rocha Dias et al. EUROPEAN JOURNAL OF CANCER
- An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients
- (2013) Yi Zhen et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Vemurafenib significantly decreases glomerular filtration rate
- (2013) C. Uthurriague et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Vemurafenib-Induced DRESS
- (2013) Kurt S. Wenk et al. JAMA Dermatology
- Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
- (2012) Vipin Yadav et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
- (2012) Bo Gao et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF around the Edges — The Paradox of BRAF Inhibitors
- (2012) Ashani T. Weeraratna NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
- (2012) Pascaline Boudou-Rouquette et al. PLoS One
- Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
- (2011) Jennifer Arrondeau et al. INVESTIGATIONAL NEW DRUGS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapid-Learning System for Cancer Care
- (2010) Amy P. Abernethy et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search